Serah Wangari Kimani

Serah Wangari Kimani

Auto-generated profile, based on publicly available information

Serah Wangari Kimani

Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMark F. Mabanglo
Mark F. Mabanglo
BWBrian Wilson
Brian Wilson
MNMahmoud Noureldin
Mahmoud Noureldin
SKSerah W. Kimani
Serah W. Kimani
AMAhmed Mamai
Ahmed Mamai
MVMasoud Vedadi
Masoud Vedadi
Proteolysis-targeting chimeras (PROTACs) have been explored for the degradation of drug targets for more than two decades. However, only a handful of E3 ligase substrate receptors have been efficiently used. Downregulation and mutation of these receptors would reduce the effectiveness of such PROTACs. We recently developed potent ligands for DCAF1, a substrate receptor of EDVP and CUL4 E3 ligases. Here, we focus on DCAF1 toward the development of PROTACs for WDR5, a drug target in various cancers. We report four DCAF1-based PROTACs with endogenous and exogenous WDR5 degradation effects and high-resolution crystal structures of the ternary complexes of DCAF1-PROTAC-WDR5. The structures reveal detailed insights into the interaction of DCAF1 with various WDR5-PROTACs, indicating a significant role of DCAF1 loops in providing needed surface plasticity, and reflecting the mechanism by which DCAF1 functions as a substrate receptor for E3 ligases with diverse sets of substrates.

16 December 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
SKSerah W. Kimani
Serah W. Kimani
SPSumera Perveen
Sumera Perveen
MSMagdalena Szewezyk
Magdalena Szewezyk
HZHong Zeng
Hong Zeng
ADAiping Dong
Aiping Dong
LHLevon Halabelian
Levon Halabelian
Cbl-b is a RING-type E3 ubiquitin ligase that is expressed in several immune cell lineages, where it negatively regulates the activity of immune cells. Cbl-b has specifically been identified as an attractive target for cancer immunotherapy due to its role in promoting an immunosuppressive tumor environment. A Cbl-b inhibitor, Nx-1607, is currently in phase I clinical trials for advanced solid tumor malignancies. Using a suite of biophysical and cellular assays, we confirm potent binding of C7683 (an analogue of Nx-1607) to the full-length Cbl-b and its N-terminal fragment containing the TKBD-LHR-RING domains. To further elucidate its mechanism of inhibition, we determined the co-crystal structure of Cbl-b with C7683, revealing the compound’s interaction with both the TKBD and LHR, but not the RING domain. Here, we provide structural insights into a novel mechanism of Cbl-b inhibition by a small-molecule inhibitor that locks the protein in an inactive conformation by acting as an intramolecular glue.

4 November 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SASuzanne Ackloo
Suzanne Ackloo
FLFengling Li
Fengling Li
MSMagda Szewczyk
Magda Szewczyk
ASAlmagul Seitova
Almagul Seitova
PLPeter Loppnau
Peter Loppnau
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Target class-focused drug discovery has a strong track record in pharmaceutical research, yet public domain data indicate that many members of protein families remain unliganded. Here we present a systematic approach to scale up the discovery and characterization of small molecule ligands for the WD40 repeat (WDR) protein family. We developed a comprehensive suite of protocols for protein production, crystallography, and biophysical, biochemical, and cellular assays. A pilot hit-finding campaign using DNA-encoded chemical library selection followed by machine learning (DEL-ML) to predict ligands from virtual libraries yielded first-in-class, drug-like ligands for 7 of the 16 WDR domains screened, thus demonstrating the broader ligandability of WDRs. This study establishes a template for evaluation of protein family wide ligandability and provides an extensive resource of WDR protein biochemical and chemical tools, knowledge, and protocols to discover potential therapeutics for this highly disease-relevant, but underexplored target class.

24 July 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
LMLena Münzker
Lena Münzker
SKSerah W. Kimani
Serah W. Kimani
MFMilan M. Fowkes
Milan M. Fowkes
ADAiping Dong
Aiping Dong
HZHong Zheng
Hong Zheng
JBJark Böttcher
Jark Böttcher
The WWE domain is a relatively under-researched domain found in twelve human proteins and characterized by a conserved tryptophan-tryptophan-glutamate (WWE) sequence motif. Six of these WWE domain-containing proteins also contain domains with E3 ubiquitin ligase activity. The general recognition of poly-ADP-ribosylated substrates by WWE domains suggests a potential avenue for development of Proteolysis-Targeting Chimeras (PROTACs). Here, we present novel crystal structures of the HUWE1, TRIP12, and DTX1 WWE domains in complex with PAR building blocks and their analogs, thus enabling a comprehensive analysis of the PAR binding site structural diversity. Furthermore, we introduce a versatile toolbox of biophysical and biochemical assays for the discovery and characterization of novel WWE domain binders, including fluorescence polarization-based PAR binding and displacement assays, 15N-NMR-based binding affinity assays and 19F-NMR-based competition assays. Through these assays, we have characterized the binding of monomeric iso-ADP-ribose (iso-ADPr) and its nucleotide analogs with the aforementioned WWE proteins. Finally, we have utilized the assay toolbox to screen a small molecule fragment library leading to the successful discovery of novel ligands targeting the HUWE1 WWE domain.

16 April 2022 in Journal of Structural Biology
Verified
Journal Article
Closed access
Stanley MakumireStanley Makumire
Stanley Makumire
SSSiyun Su
Siyun Su
BWBrandon William Weber
Brandon William Weber
JWJeremy David Woodward
Jeremy David Woodward
SKSerah Wangari Kimani
Serah Wangari Kimani
BSBryan Trevor Sewell
Bryan Trevor Sewell

19 July 2025 in Communications Biology
Verified
Journal Article
Open access
SKSerah W. Kimani
Serah W. Kimani
MNMahmoud Noureldin
Mahmoud Noureldin
BWBrian Wilson
Brian Wilson
LHLaurent Hoffer
Laurent Hoffer
SGStuart R. Green
Stuart R. Green
LHLevon Halabelian
Levon Halabelian
Human DCAF1 is a multidomain protein that plays a critical role in protein homeostasis. Its WDR domain functions as a substrate recruitment module for RING-type CRL4 and HECT family EDVP E3 ubiquitin ligases, enabling the ubiquitination and proteasomal degradation of specific substrates. DCAF1’s activity has been implicated in cell proliferation and is documented to promote tumorigenesis. Additionally, the DCAF1 WDR domain is hijacked by lentiviral accessory proteins to induce the degradation of host antiviral factors, such as SAMHD1 and UNG2. These diverse roles make DCAF1 an attractive target for therapeutic development in oncology and antiviral strategies. It is also a promising candidate for use in targeted protein degradation. We previously reported a novel ligand, OICR-8268, that targets the DCAF1 WDR domain. In this study, we present the development of OICR-41103, a potent, selective, and cell-active small molecule chemical probe for DCAF1, derived from OICR-8268. The co-crystal structure of the DCAF1-OICR-41103 complex reveals the ligand’s binding mode within the WDR central pocket, demonstrating its potential for PROTAC design and development. Notably, OICR-41103 effectively displaces the lentiviral Vpr protein from DCAF1 in both biochemical and cellular settings, highlighting its potential for the development of HIV therapeutics.